Exacerbation of myasthenia gravis during the menstrual period

被引:26
作者
Leker, RR [1 ]
Karni, A
Abramsky, O
机构
[1] Hebrew Univ Jerusalem, Dept Neurol, Jerusalem, Israel
[2] Hadassah Med Sch, Jerusalem, Israel
关键词
myasthenia gravis; menstrual period; estradiol; sex hormones; oral contraceptives; exacerbation;
D O I
10.1016/S0022-510X(98)00031-8
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Myasthenia gravis (MG) is an autoimmune disorder mediated by antiacetylcholine receptor antibodies. It has long been suspected to exacerbate during the menstrual period but this has never been adequately documented. Subjects and methods: We questioned 120 female myasthenic patients of different ages, about their myasthenic symptoms before and during the menstrual period. We also evaluated the effect of medications, pain and stress during or before the menstrual period on the exacerbation rate. Exclusion criteria were postmenopausal age and incomplete information available in the questionnaire. Results: Forty two premenopausal women with generalized disease were included in the study. Twenty eight (67%) of the patients reported exacerbation of their myasthenic symptoms 2 to 3 days prior to the menstrual period. This exacerbation persisted in 22 of them to the third day of the menstrual period. In nine of the women this clinical worsening necessitated an increased intake of medications during the days prior to menstruation. No correlation could be found between the presence of antiacetylcholine receptor antibodies, pain, stress, use of oral contraceptives or the type of antimyasthenic therapy and the rate of exacerbation before and during the menstrual period. Conclusions: (1) MG frequently exacerbates before and during the menstrual period in 67% of MG patients. (2) The rate of exacerbation is unrelated to the presence of stress or pain prior to or during the menstrual period. (3) Different therapies directed against MG, as well as oral contraceptives do not influence the clinical course. (4) Menstrual exacerbations occur in both seronegative and seropositive patients. (5) These exacerbations may frequently necessitate therapeutic changes. (C) 1998 Elsevier Science B.V.
引用
收藏
页码:107 / 111
页数:5
相关论文
共 20 条
[1]  
AHMED SA, 1985, AM J PATHOL, V121, P531
[2]   SERUM GLOBULIN IN MYASTHENIA-GRAVIS - INHIBITION OF ALPHA-BUNGAROTOXIN BINDING TO ACETYLCHOLINE RECEPTORS [J].
ALMON, RR ;
ANDREW, CG ;
APPEL, SH .
SCIENCE, 1974, 186 (4158) :55-57
[3]   SUBSET-SPECIFIC EFFECTS OF SEX-HORMONES AND PITUITARY GONADOTROPINS ON HUMAN LYMPHOCYTE-PROLIFERATION INVITRO [J].
ATHREYA, BH ;
PLETCHER, J ;
ZULIAN, F ;
WEINER, DB ;
WILLIAMS, WV .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1993, 66 (03) :201-211
[4]  
ATHREYA BH, 1993, CLIN IMMUNOL IMMUNOP, V68, P93
[5]   SERONEGATIVE MYASTHENIA-GRAVIS - CLINICAL-FEATURES, RESPONSE TO THERAPY AND SYNTHESIS OF ACETYLCHOLINE-RECEPTOR ANTIBODIES INVITRO [J].
BIRMANNS, B ;
BRENNER, T ;
ABRAMSKY, O ;
STEINER, I .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1991, 102 (02) :184-189
[6]  
BRENNER T, 1978, ISRAEL J MED SCI, V14, P986
[7]  
CARBONE A, 1986, J CLIN LAB IMMUNOL, V21, P87
[8]   MEDICAL PROGRESS - MYASTHENIA-GRAVIS [J].
DRACHMAN, DB .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (25) :1797-1810
[9]  
FLOYD RC, 1992, OBSTET GYN CLIN N AM, V19, P719
[10]  
Gilmore W, 1997, J IMMUNOL, V158, P446